Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who can’t get the blockbuster drug through insurance.

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals , whose medicines are part of the second round of ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Spring has nearly sprung and round two of the Inflation Reduction Act (IRA)’s negotiation period has begun. | All of the ...

All pharmaceutical manufacturers, including Novo Nordisk (NYSE:NVO) and Teva Pharmaceuticals, have agreed to participate in ...

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured and underinsured individuals to be able to pay cash for its weight loss ...

Medicare enrollees can receive coverage for ... to the FDA-approved versions of the drugs and this new program from Novo Nordisk appears to cater to individuals who were accustomed to getting ...

Novo Nordisk NVO shares have lost 21% in the past ... again leading to a loss of market share. Medicare has also selected NVO’s semaglutide medicines for the second round of price negotiations ...

Novo Nordisk said Wednesday it will sell Wegovy ... said the federal government would negotiate maximum prices that Medicare pays for Ozempic and Wegovy—among other prescription drugs—under ...